ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.188,34
-1,00%
S&P 500
5.214,08
0,51%
US Dollar vs BRL
5,1423
0,00%
Bitcoin
62.925,09
-0,20%
Brent Oil
84,18
0,27%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Vanda Pharmaceuticals Inc (VNDA)

  7. Vanda Pharmaceuticals Inc (VNDA) Notícias

VNDA

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:VNDA
DataHoraFonteTítuloCódigoCompanhia
09/05/202418:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VNDAVanda Pharmaceuticals Inc
09/05/202408:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VNDAVanda Pharmaceuticals Inc
08/05/202417:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
08/05/202417:01PR Newswire (US)Vanda Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:VNDAVanda Pharmaceuticals Inc
07/05/202412:16PR Newswire (US)Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future PakNASDAQ:VNDAVanda Pharmaceuticals Inc
30/04/202417:30PR Newswire (US)Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
25/04/202409:05GlobeNewswire Inc.Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda PharmaceuticalsNASDAQ:VNDAVanda Pharmaceuticals Inc
22/04/202420:13PR Newswire (US)Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA LitigationNASDAQ:VNDAVanda Pharmaceuticals Inc
17/04/202411:21PR Newswire (US)Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanNASDAQ:VNDAVanda Pharmaceuticals Inc
17/04/202410:02PR Newswire (US)Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future PakNASDAQ:VNDAVanda Pharmaceuticals Inc
03/04/202411:25AllPennyStocks.comBiotech Catches Major Premarket Bid Following FDA ApprovalNASDAQ:VNDAVanda Pharmaceuticals Inc
02/04/202419:10PR Newswire (US)Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I DisorderNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202418:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202409:00PR Newswire (US)Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of InsomniaNASDAQ:VNDAVanda Pharmaceuticals Inc
04/03/202423:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
16/02/202418:31Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:VNDAVanda Pharmaceuticals Inc
08/02/202409:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VNDAVanda Pharmaceuticals Inc
07/02/202418:02PR Newswire (US)Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VNDAVanda Pharmaceuticals Inc
31/01/202418:30PR Newswire (US)Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
31/01/202411:00PR Newswire (US)Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of OnychomycosisNASDAQ:VNDAVanda Pharmaceuticals Inc
30/01/202414:35PR Newswire (US)Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
26/01/202400:05PR Newswire (US)Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.NASDAQ:VNDAVanda Pharmaceuticals Inc
25/01/202415:07PR Newswire (US)Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and HepatologyNASDAQ:VNDAVanda Pharmaceuticals Inc
23/01/202413:52Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VNDAVanda Pharmaceuticals Inc
23/01/202411:15PR Newswire (US)Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2SNASDAQ:VNDAVanda Pharmaceuticals Inc
19/01/202418:57Dow Jones NewsVanda Pharma's Trade Secrets Suit Against FDA Moves ForwardNASDAQ:VNDAVanda Pharmaceuticals Inc
19/01/202417:56PR Newswire (US)Federal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug AdministrationNASDAQ:VNDAVanda Pharmaceuticals Inc
17/01/202417:46PR Newswire (US)Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical PsychiatryNASDAQ:VNDAVanda Pharmaceuticals Inc
12/01/202414:21PR Newswire (US)Vanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved DrugsNASDAQ:VNDAVanda Pharmaceuticals Inc
04/01/202418:30PR Newswire (US)Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare ConferenceNASDAQ:VNDAVanda Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:VNDA

Seu Histórico Recente

BOV
IFCM3
Infracommerce Caxaas ON
BOV
VVEO3
CM Hospitalar ON
BOV
HBRE3
HBR Realty Empreendiment... ON
BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
TELB4
TELEBRAS PN
BOV
CMIN3
CSN Mineracao S.A ON
BOV
COGN3
COGNA ON
BOV
LUPA3
LUPATECH ON
BOV
PDTC3
Padtec ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
CASH3
Meliuz S.A ON
BOV
RNEW4
RENOVA PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados